What do these icons mean?
- You can view this document directly.
- You need to login to view this document.
- You need to request access to view this document.
As we began pulling together content for this latest issue of BioPharma Digest, a very clear theme arose. During our review of industry news, we realized that many of the partnerships, acquisitions and other portfolio diversification activities happening in the industry largely center around the generics and biosimilars sectors of the industry.
Due to dwindling drug sales and innovation at home and the growing need to be competitive in emerging markets, the pharma industry has become laser-focused on generic drugs as a means to diversify portfolios and create brand-name awareness in target markets such as India, China and Latin America. Likewise, the biosimilars sector is enjoying increased activity. An estimated $130 billion worth of biologic drugs will lose patent exclusivity over the next ten years, and many are eager to compete in this lucrative market.